Abstract
Small bowel adenocarcinoma (SBA) is a rare but increasing cause of gastrointestinal malignancy, being both a diagnostic and therapeutic challenge. The goal of treatment is margin negative resection of a lesion and local lymphadenectomy, followed by modern adjuvant chemotherapy combinations in selected cases. Improved outcomes in patients with SBA are encouraging, but elucidation of mechanisms of carcinogenesis and risk factors as well as improved treatment for this malignancy is very needed.
Keywords:
SBA; Small bowel adenocarcinoma; chemotherapy; small bowel; surgery.
MeSH terms
-
Adenocarcinoma / diagnosis
-
Adenocarcinoma / physiopathology
-
Adenocarcinoma / therapy*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Carcinogenesis
-
Chemotherapy, Adjuvant
-
Digestive System Surgical Procedures
-
Double-Balloon Enteroscopy
-
Duodenal Neoplasms / diagnosis
-
Duodenal Neoplasms / physiopathology
-
Duodenal Neoplasms / therapy*
-
Early Diagnosis
-
Humans
-
Ileal Neoplasms / diagnosis
-
Ileal Neoplasms / physiopathology
-
Ileal Neoplasms / therapy*
-
Intestine, Small / pathology*
-
Jejunal Neoplasms / diagnosis
-
Jejunal Neoplasms / physiopathology
-
Jejunal Neoplasms / therapy*
-
Lymph Node Excision
-
Prognosis
-
Risk Factors
-
Treatment Outcome